Patients with prostate adenocarcinoma treated with radical prostatectomy;
Tumour stage pT2-4, R0-1, pN0, or cN0, cNx according to the UICC TNM 2009, only with Gleason score available;
No lymph node or distant metastases. A recent PSMA-PET scan (\< 60 days) without evidence of lymph node or distant metastases;
PSA progression after prostatectomy defined as two consecutive rises with the final PSA \> 0.1 ng/mL or 3 consecutive rises. The first value must be measured at least 6 weeks after radical prostatectomy;
PSA at inclusion \< 1.0 ng/mL;
WHO performance status 0-2 at inclusion;
Age at inclusion between 18 and 80 years;
Written (signed and dated) informed consent prior to registration.
You may not be if
Prior pelvic irradiation, (chemo)hormonal therapy or orchiectomy;
Previous or concurrent active invasive cancers other than superficial non-melanoma skin cancers;
Patients with positive nodes or with distant metastases based on the surgical specimen of lymphadenectomy or the following minimum diagnostic workup: PSMA-PET/CT scan, 60 days prior to registration;
Double-sided metallic hip prosthesis;
Inability or unwillingness to understand the information on trial-related topics, to give informed consent or to fill out QoL questionnaires.
Clareo Health | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
